Keyphrases
Health Care Costs
100%
Fixed Dosing
100%
Checkpoint Inhibitors
100%
Extended Interval
100%
Pembrolizumab
42%
Healthcare Payer
42%
Economic Evaluation
28%
Sensitivity Analysis
28%
Extended Interval Dosing
28%
Israel
14%
Treatment Duration
14%
Dose Rate
14%
Disease Course
14%
Cost Increase
14%
Economic Impact
14%
Immune Checkpoint Inhibitors
14%
Drug Administration
14%
Bloodstream
14%
Dose Intensity
14%
Progression-free Survival
14%
Simulated Patient
14%
Survival Curve
14%
U.S. Food
14%
Drug Costs
14%
Administration Costs
14%
Patient Profile
14%
Overall Cost
14%
Cost Estimation
14%
Second-line Therapy
14%
Platinum Resistance
14%
Metastatic Urothelial Cancer
14%
Imaging Cost
14%
Dosing Strategy
14%
Course Profile
14%
Pharmacoeconomic Model
14%
Drug Imaging
14%
Nursing and Health Professions
Health Care Cost
100%
Pembrolizumab
100%
Health Care
100%
Base
66%
Imaging
66%
Economic Evaluation
66%
Food and Drug Administration
66%
Diseases
66%
Malignant Neoplasm
33%
Treatment Duration
33%
Infusion
33%
Survival Rate
33%
Disease Course
33%
Progression Free Survival
33%
Pharmacoeconomics
33%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
100%
Base
66%
Diseases
66%
Malignant Neoplasm
33%
Survival Rate
33%
Progression Free Survival
33%
Disease Course
33%
Immune Checkpoint Inhibitor
33%
Pharmacoeconomics
33%